Evidence map›Paper›PMID 40443837›Full record

ReviewCureus2025

The Integration of Artificial Intelligence Into Precision Medicine for Neuro-Oncology: Ethical, Clinical, and Nursing Implications in Immunotherapy Care.

Victoria M Ajibade, Chidinma S Madu

Abstract readReview
In one paragraph

Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Victoria M AjibadePediatric Critical Care, Duke University Health System, Durham, USA.
Chidinma S MaduNeuro-Oncology, Duke University Health System, Durham, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper explores how artificial intelligence (AI) is being woven into precision medicine for neuro-oncology, highlighting its ethical, clinical, and nursing implications in the realm of immunotherapy. With AI-powered diagnostics and predictive analytics, we're seeing a boost in treatment accuracy, which paves the way for more personalized and effective care. On the clinical side, AI is fine-tuning targeted therapies, leading to better patient outcomes and less treatment-related toxicity. However, ethical concerns pop up around data privacy, algorithmic bias, and fair access to these AI-driven treatments. Nurses are at the forefront of tackling these issues, ensuring that care remains patient-centered, monitoring AI-assisted interventions, and grappling with ethical challenges. Their role in education and advocacy is crucial in connecting the dots between AI innovations and compassionate care. As AI continues to advance, it's vital for different disciplines to work together to tap into its potential while maintaining ethical standards and enhancing care in neuro-oncology.

Indexed as

immunotherapyneuro-oncologynursingpatient careprecision medicinetargeted therapytechnology integration

Identifiers

PMID40443837
PMCPMC12121462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.